Journal of Medicinal Chemistry p. 1600 - 1606 (1989)
Update date:2022-08-03
Topics:
Smith, Elizabeth M.
Swiss, Gerald F.
Neustadt, Bernard R.
McNamara, Paul
Gold, Elijah H.
et al.
The synthesis of spirapril (5), spiraprilat (25), their RSS stereoisomers, and their glycyl (18b) and lysyl (36, 37) analogues is described.These compounds were evaluated in vivo for inhibition of angiotensin converting enzyme (ACE), and selected compounds were evaluated for in vitro ACE inhibition (spirapril ID50 16 μg/kg; spiraprilat IC50 0.8 nM, ID50 8 μg/kg).In anesthetized rats, iv, esters 5 and 36 are more potent than enalapril, and diacids 25 and 37 are more potent than enalaprilat in vitro.In the conscious rats, orally, 5 and enalapril (2) showed potent and sustained activity at doses of 0.03-1 and 0.1-1 mg/kg, respectively.From this work, spirapril was selected for clinical evaluation as an antihypertensive agent.
View MoreChengdu Chengnuo New-Tech Co., Ltd
Contact:0086-028-85749078
Address:4 Jiuyang road,Jiulong industrial port,Chengdu, China
Contact:17316303296
Address:240 Amboy Ave
Qingdao XinYongAn Chemicals Co., Ltd
Contact:+86-532-81107967
Address:Chengyang dual-port industrial park by the sea,Qingdao
Contact:+86-20-32051076
Address:1105,Building A, International Business Incubator,Science City
Shuanghe Bio-Technology Limited
Contact:+86-571-61710758,18968016640
Address:Jinqiao north road 916# Fuyang
Doi:10.1055/s-0039-1690103
(2019)Doi:10.1016/0040-4020(80)80085-8
(1980)Doi:10.1016/j.tet.2004.06.022
(2004)Doi:10.1016/j.steroids.2018.09.010
(2018)Doi:10.1246/bcsj.53.2091
(1980)Doi:10.1039/P19850001725
(1985)